Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Squamous Cell Carcinoma Clinical Trials

A listing of Squamous Cell Carcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (10) clinical trials

Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma

This clinical trial is the first to evaluate the safety and feasibility of a humanized OX40 agonist, MEDI0562, in the pre-operative setting for patients with head and neck squamous cell carcinoma or melanoma. Patients will be randomly assigned to one of two MEDI0562 administration schedules; initially 5 patients will enroll ...


Radiotherapy With Pembrolizumab in Metastatic HNSCC

This is an open-label, randomized, prospective, multicenter phase II clinical trial of pembrolizumab with or without local radiotherapy in patients with recurrent and/or metastatic HNSCC after progression to platinum-based therapy. All patients will receive pembrolizumab 200mg absolute dose administered every third week. Patients in treatment arm A will receive radiotherapy ...


Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS

Subject enrolment may proceed with information available on tumor HRAS status previously generated during the pre-screening phase, but all subjects must consent to provide tumor slides (or tumor tissue block) from a prior diagnostic biopsy for a retrospective testing of RAS gene status, including T81C polymorphism, and other potential biomarkers ...


Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC

Stage 1: Neoadjuvant chemoradiation (CRT): Stage 2: Evaluation of clinical responses Evaluation will be done at 31 weeks after completing the last fraction of radiotherapy. Evaluation will be performed with panendoscopy, endoscopic ultrasonography (EUS), computed tomography (CT), and positron emission tomography (PET). Stage 3: Surgery Patients will receive esophagectomy with ...


Intralesional 5-Fluorouracil (5FU) Topical Imiquimod Treatment for SCC

Squamous cell carcinoma (SCC) of the lower extremity is a distinct subset of cutaneous squamous cell carcinomas which tend to occur multiply in elderly women. In contrast, the majority of cutaneous SCCs occur on the head and neck, and in men more than women. Histopathological studies of lower extremity SCCs ...


EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer

This is a randomised phase II study comparing the efficacy of avelumab alone with avelumab + cetuximab combination in patients with platinum-resistant advanced or metastatic head & neck cancer. The randomised phase II part of the trial will be preceded by a safety run-in.The objective of the safety run in ...


A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck

This is a randomized, open-label, multicenter, phase II trial. Patients with recurrent or metastatic squamous cell carcinoma of the head and neck will be enrolled in this trial will initiate palliative systemic treatment with nivolumab monotherapy (3 mg/kg Q2W). Tumor response will be assessed after 4, 8, 12, 18 and ...


SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer

Patients with previously untreated advanced or metastatic esophageal squamous cell cancer are recruited to this prospective non-randomised study comprising two separate cohorts. Patients will receive SHR-1210, a novel anti-PD-1 antibody, with apatinib and either irinotecan or paclitaxel liposome plus nedaplatin. The primary endpoint is to determine the progression free survival ...


ctDNA as a Biomarker for Treatment Response in HNSCC

Tumours continually shed DNA into the circulation, where it can be accessed. This circulating tumour DNA (ctDNA) directly reflects tumour burden and has great potential to be a sensitive biomarker for treatment recurrence. These "liquid biopsies" could give a more real-time picture of the genomic status and evolution of a ...

Phase N/A

A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

PRIMARY OBJECTIVES: I. To determine the maximally tolerated and recommended phase 2 dose of abexinostat in combination with anti-PD-1/PD-L1 checkpoint inhibitor (CPI). (Dose escalation) II. To determine the objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria in patients treated with abexinostat in combination with ...